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by high viremia, but falls following the onset of antiretroviral
therapy (ART). Relatively little has been reported on the subse-
quent stability of theHIV-specific T cell response in individuals
on durable therapy. Such data are critical for powering clinical
trials testing T cell-based immunotherapies. In a cross-
sectional study, HIV-specific T cell responses were detectable
by ex vivo interferon (IFN)-g ELISpot (average 1,100 spot-
forming units [SFUs]/106 peripheral blood mononuclear cells)
in persons living with HIV (PLWH; n = 34), despite median
durable ART suppression of 5.0 years. No substantial associa-
tion was detected between the summed HIV-specific T cell
response and the size of the replication-competent HIV reser-
voir. T cell responses were next measured in participants
sampled weekly, monthly, or yearly. HIV-specific T cell re-
sponses were highly stable over the time periods examined;
within-individual variation ranged from 16% coefficient of
variation (CV) for weekly to 27%CV for yearly sampling. These
data were used to generate power calculations for future immu-
notherapy studies. The stability of the HIV-specific T cell
response in suppressed PLWH will enable powered studies of
small sizes (e.g., n = 6–12), facilitating rapid and iterative
testing for T cell-based immunotherapies against HIV.Received 20 June 2019; accepted 26 July 2019;
https://doi.org/10.1016/j.omtm.2019.07.008.
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To date, over 18.5 million people receive combination antiretroviral
therapy (ART) to control HIV viremia and limit or restore CD4
T cell depletion. ART is life-long; interruption of therapy results in
viral rebound within weeks for most individuals.1,2 The success of
ART against HIV has been an outstanding medical achievement
saving many millions of lives. Effective HIV treatment does not
ameliorate the clinical impact of ongoing immune activation,
increased risk of cardiovascular disease and malignancies, and
toxicity caused by ART. Nor does ART lessen the impact of HIV
stigma on persons living with HIV (PLWH). Lifelong ART also has
significant societal health costs, with the estimated lifetime costs for
HIV-related treatment for one individual estimated at $370,000.3
HIV cure, whether complete eradication of the replication-competentMolecular Therapy: Methods & C
This is an open access article under the CC BY-NHIV reservoir or induction of ART-free remission, therefore remains
the ultimate goal for both HIV+ individuals and researchers.
The induction of HIV-specific CD8+ T cells is likely to be an important
component of both eradication and remission-focused cure strategies.
HIV-specific CD8+ T cell responses are detectable in all HIV-infected,
untreated individuals.4,5 Although CD8+ T cells are broadly critical to
HIV host immunity, they are more effective in some individuals than
others.6 In viremic individuals, the HIV-specific CD8+ T cell response
is dynamic, with new T cell responses emerging as others decline in
response to viral escape.7,8 As infection proceeds, chronic antigenic
drive also leads to loss of functionality and immune exhaustion.9
Current ART regimens decrease HIV levels from >105–107 to
<200 copies/mL in the majority of individuals within 6 months,
concomitantwith a recoveryofCD4Tcell levels in the blood.10Multiple
groups have reported that HIV-specific T cell responses remain
detectable ex vivo in individuals on durable virus suppression; however,
there are very limited longitudinal data describing the HIV-specific
T cell response in long-term ART-suppressed individuals.11–15
In this study, we investigated the strength, targeting, andmaintenance
of the HIV-specific T cell response. We show HIV-specific T cell re-
sponses are maintained at relatively high frequencies and are stable
over weeks, months, and years. These data are consistent with
ongoing antigen presentation to CD8+ T cells by HIV-infected cells
during durable suppression and facilitate more accurate powering
of T cell immunotherapy studies.RESULTS
Study Cohorts
All participants were adults (R18 years of age) with documented HIV
infection. For cross-sectional and weekly and monthly longitudinallinical Development Vol. 15 December 2019 ª 2019 The Authors. 9
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Cross-Sectional Cohort (n = 34) Characteristics
Characteristic All Participants (n = 34)
Gender 27 males (79%), 7 females (21%)
Race 16 Black (47%), 18 White (53%)
Ethnicity 0% Hispanic or Latino
Onset ARTa 8 acute, 26 chronic
Median Range
Age, years (range) 49 20–66
CD4 nadir (cells/mL) 287 9–789
Years of ART suppressionb 5.0 0.6–13.2
IUPMc 0.68 0.02–8.3
aAcute: combination antiretroviral therapy (cART) begun within 30 days of negative or
discordant HIV antigen test.
bDurable suppression defined as time from %40 copies/mL to date of T cell measure-
ment. Numbers based on 33 participants because status of one participant unknown.
cIUPM (infectious units per million) numbers based on study data of 19 participants.
Table 2. Longitudinal Cohort (n = 32) Characteristics
Weekly, Monthlya Yearlya




1 Black, 1 Pacific
Islander, 7 White
Race 0% Hispanic or Latino 11% Hispanic or Latino
Onset of ARTb 4 acute, 19 chronic all chronic
Age, years (range)c 48 (20–66) 41 (37–58)
CD4 nadir (cells/mL) 334 (9–789) 190 (10–397)
Years of ART suppressiond 4.8 (0.55–8.4) 2.4 (1.5–8.2)e
aWeekly and monthly enrolled at UNC; yearly enrolled at UCSF.
bAcute: ART begun within 30 days of negative or discordant HIV antigen test.
cAge at first T cell measurement.
dDurable suppression for UNC cohort defined as time from %40 copies/mL to first
T cell measurement. UCSF (SCOPE cohort) defined as time from %500 copies/mL to
first T cell measurement.
eConservative calculation because of limited clinical data prior to 2001 study enrollment.
Molecular Therapy: Methods & Clinical Developmentstudies, samples came from participants enrolled at the University of
North Carolina at Chapel Hill. For the yearly longitudinal study, sam-
ples were obtained from participants enrolled at the University of
California, San Francisco (UCSF), through the Observational Study
of the Consequences of the Protease Inhibitor Era (SCOPE) cohort.
Tables 1 and 2 summarize basic demographic and clinically impor-
tant details relative to the cohorts. Institutional review board (IRB)
approvals are detailed in the Materials and Methods.
HIV-Specific T Cell Responses in HIV-Seropositive Durably
Suppressed Individuals Remain Detectable and Do Not
Correlate Strongly with Pre-ART CD4 Nadir or the Replication-
Competent Reservoir
A cross-sectional analysis of HIV-specific T cell responses
measured by ex vivo interferon (IFN)-g enzyme-linked immune
absorbent spot (ELISpot) was performed in HIV+ ART+ partici-
pants (n = 34). Mean durable ART suppression prior to testing
was 5.0 years (range: 0.6–13.2 years). In all participants, HIV-spe-
cific T cell responses to protein pools spanning HIV Clade B (Gag,
Pol, Env, and Acc composed of Nef, Rev, Tat, Vif, and Vpu) were
clearly detected (Figure 1A). The total HIV-specific T cell
response, defined as the sum of the individual HIV protein peptide
pools, was 1,198 spot-forming units (SFUs)/106 peripheral blood
mononuclear cells (PBMCs; range: 164–4,156 SFUs/106 PBMCs),
comparable with other reports of PLWH on durable ther-
apy.11,14,16 Consistent with observations in untreated HIV infec-
tion,17 Gag-specific T cell responses were immuno-prevalent in
terms of the proportion of reactive participants (100%, 34/34
reactive) and magnitude (mean = 394 SFUs/106 PBMCs, range
35–1,298 106 PBMCs). The high frequency of targeting of Gag,
Pol, and Nef proteins was similar to previous reports of treated
HIV infection.15,17
Measurements of HIV-specific T cell responses to pools of HIV pep-
tides have been previously reported as an accurate and cell-saving10 Molecular Therapy: Methods & Clinical Development Vol. 15 Decemapproach to monitoring the total HIV-specific T cell response.18,19
Prior experimentally confirmed optimal CD8+ T cell epitopes
collated and listed by the Los Alamos National Laboratory HIV
database were synthesized and combined into two peptide pools,
CTL-A and CTL-B.20 CTL-A contained optimal epitopes found in
HIV Gag and Nef, whereas CTL-B contained epitopes found in
HIV proteins other than Gag and Nef.20 T cell responses to both
the CTL-A and -B pools were consistently detected within the
cohort (either CTL-A or -B: n = 33/34, CTL-A: n = 33/34, CTL-B:
n = 31/34). Within reactive participants, the CTL-A pool induced
higher T cell responses than the CTL-B pool (CTL-A mean = 667
SFUs/106 PBMCs [range 65–2,430 SFUs/106 PBMCs] versus CTL-
B mean = 436 SFUs/106 PBMCs [range 34–1,803 SFUs/106
PBMCs]). We compared the total HIV-specific T cell response
with the sum of CTL-A and CTL-B pools (CTLA+B) for each partic-
ipant (Figure 1B). A strong correlation was observed (r = 0.75,
Spearman rank, p % 0.001, n = 34 pairs).
We next examined whether clinical and virological characteristics
were associated with the frequency of post-ART HIV-specific
T cells. No difference in summed T cell response to HIV protein pools
was detected (p = 0.234, Mann-Whitney test, unpaired) between men
(1,147 SFUs/106 PBMCs, range 164–4,156) and women (1,395
SFUs/106 PBMCs, range 311–3,611), nor was there a detectable asso-
ciation between age and HIV-specific T cell magnitude (r = 0.02,
Spearman rank, p = 0.91, n = 34 pairs). The magnitude of the
measured HIV-specific T cell response was broadly the same whether
participants initiated treatment in acute infection or chronic HIV
infection (acute 1,202 SFUs/106 PBMCs versus chronic 1,197
SFUs/106 PBMCs). No association was detected between pre-ART
CD4 nadir (range 9–789 cells/mL) and HIV-specific T cell response
(r = 0.03, p = 0.87, Spearman rank, n = 34 pairs; Figure 1C). Simi-
larly, no strong correlation was detected between T cell responses to
either the summed total or individual HIV proteins and the size of the
replication-competent virus measured by the quantitative viralber 2019
Figure 1. HIV-Specific T Cell Responses Are
Detectable in HIV-Seropositive, ART-Suppressed
Individuals
(A) HIV-specific T cell responses from HIV-seropositive
durably suppressed individuals (n = 34) were quantified by
ex vivo IFN-g ELISpot assay. PBMCs were stimulated with
either HIV Clade B peptides pooled by protein (Gag, Env,
Pol, Nef, or ACC = Rev, Tat, Vif, Vpu, or Vpr) or previously
defined HIV CD8+ optimal epitopes split into two pools,
containing either a pool of Gag Nef optimal epitopes
(CTL-A) or a pool of non-Gag Nef (“other,” CTL-B) optimal
epitopes. Data are shown as boxplots (25th–75th inter-
quartile range), with median and whiskers showing mini-
mum to maximum datapoints. Dotted line = 30 SFUs/106
PBMCs. Spearman rank correlations of total HIV-specific
T cell response Gag+Pol+Env+Nef+Acc against (B)
summed optimal T cell epitopes (r = 0.751, p < 0.001,
n = 34), (C) CD4 nadir (r = 0.003, p = 0.98, n = 19, dotted
line indicated CD4 T cells/mL = 100), and (D) the size of the
replication-competent reservoir as measured by infec-
tious units per million (IUPM) (r = 0.224, p = 0.37, n = 17).
Red dots (B–D) indicate participants who started ART in
acute HIV infection.
www.moleculartherapy.orgoutgrowth assay (QVOA) (r = 0.22, Spearman rank, p = 0.37, n = 18
pairs; Figure 1D; Table S1).HIV-Specific T Cell Responses Are Stable over Weeks, Months,
and Years
Durably ART-suppressed PLWHwere sampled either weekly (n = 14;
Figure 2A), monthly (n = 9; Figure 2B), or yearly (n = 9, every 1–3
years for up to 8.5 years) for up to eight visits. T cell responses to
CTL-A and CTL-B were measured at each time point. In each group,
the magnitude of the HIV-specific T cell response was remarkably
stable. Percent coefficient of variation (%CV) was calculated to sum-
marize within-individual variability over time. Although overall %CVFigure 2. HIV-Specific T Cell Responses Are Stable over Weeks, Months, and Years
(A–C) HIV-specific T cell responses to HIV T cell optimal epitopes (sum of Gag /Nef and optimal “other” pools) we
(n = 15), (B) monthly (n = 9), or (C) yearly (n = 9). Each colored line represents a different HIV-infected, durably ART
average of replicate wells ± SEM.
Molecular Therapy: Methods & Cliwas low, a numerically higher %CV was
observed in the yearly group (median CV:
26.9%; 95% confidence interval [CI] for the
pseudo-median: 14.9%, 39.4%) compared withthe weekly (16.2%; CI: 9.6%, 27.1%) and monthly (14.5%; CI: 9.1%,
26.1%) groups.
Parameters Influencing T Cell Measurements over Time
We examined a number of measurements, including technical
measures such as CV between independent cell counts, T cell qual-
ity measures such as total cell recovery and viability, and storage
quality measures such as time between original sampling and assay
testing (Table 2; Tables S3 and S4). Non-parametric Kendall’s
Tau rank correlations were performed between either a Z score
calculated for a participant’s HIV-specific T cell response or the
raw T cell measurement and each assay variable. The Z score anal-
ysis informed assay reliability, whereas the raw T cell analysisre measured in durably suppressed individuals (A) weekly
-suppressed individual. Data shown are mock-subtracted,
nical Development Vol. 15 December 2019 11
Table 3. Variability of HIV-Specific T Cell Responses Measured Weekly Was Not Associated with Assay Covariates
Weekly CTLA+B Z Scores of Within-Individual Variability Raw CTLA+B Measurements
Variable Range Kendall’s Tau Estimate 95% LCL 95% UCL Kendall’s Tau Estimate 95% LCL 95% UCL
No. of measures over time 4–8 0.00 0.01 0.01 0.02 0.45 0.49
Days between visit and thaw 0–322 0.09 0.01 0.19 0.02 0.34 0.29
Days since first measurement 0–76 0.08 0.01 0.16 0.30 0.08 0.67
CV between independent cell counts (n = 3) 0.60–19.14 0.02 0.19 0.16 0.11 0.27 0.05
Total cell count (106) 3.23–17.43 0.04 0.06 0.15 0.02 0.23 0.19
Average viable cell count (/mL) 0.87–5.40 0.02 0.05 0.09 0.15 0.49 0.20
% PBMC recovery 32.37–143.50 0.08 0.06 0.22 0.08 0.24 0.09
Molecular Therapy: Methods & Clinical Developmentinvestigated whether assay variables directly impacted T cell
measurements.
Not surprisingly, given the stability of HIV-specific T cell responses
observed over time, most Z score correlations were not detected at
a 5% significance level (Table 3; Tables S3 and S4). Mean SFU of
the mock-stimulated was inversely correlated with total CTLA+B
T cell response for participants measured yearly (Kendall’s Tau =
0.36; 95% CI: 0.63, 0.10).21 Although some yearly data were
excluded for high background (see Materials and Methods), the
mean of the mock wells in yearly samples included for analysis re-
mained higher than the weekly and monthly samples (yearly
mean = 14.6 SFUs/106 PBMCs versus weekly and monthly mean =
4.4 SFUs/106 PBMCs).
Overall, these analyses suggest that HIV-specific T cell responses were
not measurably impacted by the range of variation observed in
technical parameters such as cell recovery and large differences in
the period of cell storage. However, as expected, increasing non-
specific background in negative control wells resulted in lowered
assay sensitivity.
Minimal Variation of the Baseline HIV-Specific T Cell Response
Allows for Design of Small but Powered Intervention Studies
Baseline HIV-specific T cell responses were used to inform power
calculations for future therapeutic vaccine studies (all data are pro-
vided in Table S2). To calculate power for a continuous variable
such as T cell magnitude, one must identify beforehand a mean-
ingful effect size (e.g., vaccination will induce a geometric mean
ratio [GMR] of 2.0, or equivalently a 2-fold change), a level of
significance (e.g., alpha = 0.01 or 0.05), and a range of feasible
sample sizes.
Based on recent therapeutic HIV vaccine studies (B. Mothe et al.,
2017, Retroviruses Opportunistic Infect., abstract),14,16,22 we
considered an effect size of GMR = 2.0, significance level of
0.05, and group sizes of 6, 8, and 12 participants per vaccine group
relevant to HIV vaccine testing. The outcome measure (HIV-
specific T cell responses) was assumed to follow a log-normal dis-
tribution in order to generate simulated datasets. The baseline12 Molecular Therapy: Methods & Clinical Development Vol. 15 Decemvariation data herein were used to estimate: (1) between-individual
variation and (2) within-individual correlation in the weekly and
monthly groups. Effectively, baseline variation data identified the
“noise” against which to detect a vaccine-induced change in
T cell response.
To calculate between-individual variation, measured as SD, the
average of two baseline measurements per individual from weekly
and monthly participants was used. A SD of 0.8 at baseline was
observed using log-transformed CTLA+B measurements. The same
SD was assumed for post-vaccination HIV-specific data (because
post-vaccination data were not available at the time of study design,
one potential limitation to this analysis).
Two approaches were taken to estimate within-individual correla-
tion in the natural log-transformed CTLA+B T cell response: Pear-
son’s correlation between the natural log-transformed CTLA+B
T cell response at baseline and 9 weeks (±3 weeks), and an exchange-
able working correlation estimate fit using generalized estimating
equations (GEE) across all baseline measurements. Both methods
estimated a within-individual correlation >0.9. Using an exact
Wilcoxon signed-rank test under these assumptions, a group size
of n = 6 participants provides 85% power to detect a GMR of 2 or
greater (Table 4).
In a paired, pre- versus post-vaccination design, high levels of statis-
tical power are more likely to be achieved when the within-individ-
ual correlation is high. To allow for the possibility that in future vac-
cine studies, baseline and post-vaccine responses may not be as
strongly correlated within individual as baseline responses alone
(e.g., not all vaccine recipients may respond consistently to vaccina-
tion), we also explored a range of within-pair correlations from
0.5 to 0.9 (Table 4). Due to the limited variance of HIV-specific
T cell responses, we estimated >80% power to detect a GMR of 2
in the HIV-specific T cell response with a group size of 12 partici-
pants, using a within-pair correlation as low as 0.6 (Table 4). Lastly,
we used these baseline variation data to calculate the ability to detect
changes in GMR <2 in group sizes of 12 (Table 5). When within-pair
correlations are strong (0.9), there is >80% power to detect a fold-
change in GMR as low as 1.5.ber 2019
Table 4. Power to Detect 2-Fold Change in the GMR of the HIV-Specific T
Cell Response from Pre- to Post-vaccine








0.5 6 41% 27%
8 56% 49%
12 78% 73%
0.6 6 48% 34%
8 65% 58%
12 86% 83%
0.7 6 60% 43%
8 77% 71%
12 94% 92%
0.8 6 76% 58%
8 91% 86%
12 99% 98%
0.9 6 96% 85%
8 >99.9% 99%
12 >99.9% >99.9%
Power calculations were based on weekly and monthly CTLA+B data (UNC cohort).
A between-individual SD = 0.8 for natural log-transformed CTLA+B was assumed
for both pre- and post-vaccine, based on baseline data presented herein.
aA GMR = 2 corresponds to a 2-fold change between pre- and post-vaccine.
bCorrelation between pre- and post-vaccination paired measurements.
Table 5. Power to Detect Various Fold Changes in the GMR of the HIV-









1.3 0.7 27% 24%
0.8 38% 49%
0.9 64% 73%
1.5 0.7 54% 34%
0.8 72% 67%
0.9 95% 88%
1.7 0.7 77% 59%
0.8 91% 92%
0.9 >99% 99%
3.0 0.5 99% 98%
Power calculations were based on weekly and monthly CTLA+B data (UNC cohort). A
between-individual SD = 0.8 for natural log-transformed CTLA+B was assumed for
both pre- and post-vaccine, based on baseline data presented herein.
aCorrelation between pre- and post-vaccination paired measurements.
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In this study, the strength and targeting of HIV-specific T cell re-
sponses were examined cross-sectionally and longitudinally in
durably suppressed PLWH. The cross-sectional analysis confirmed
earlier observations that T cell targeting of HIV proteins in HIV+
ART+ individuals is similar to the patterns observed in untreated
chronic infection, most notably the immuno-prevalence of Gag.17
T cell responses to previously identified optimal HIV CD8+ T cell epi-
topes were also examined.20 The majority of these epitopes represent
immuno-prevalent epitopes targeted by CD8+ T cells in chronic
untreated HIV infection.23 An association was observed between
the total summed T cell response to the HIV Clade B proteome and
the summed response to these optimal epitope pools, suggesting
that post-ART specific T cell responses strongly overlap with im-
muno-prevalent CD8+ T cell responses in untreated infection.
It is common for HIV immunotherapy studies to include a mini-
mum threshold for pre-ART CD4 nadir, the rationale being that im-
mune depletion during untreated infection may limit participant
responsiveness to T cell immunotherapy. Here, consistent with a
previous report,24 no meaningful association was detected between
the size of the HIV-specific T cell response and the wide range of
CD4 nadir in participants in this study cohort. Although pre-ART
CD4 depletion may impact T cell parameters not measured in this
study, for immunotherapy trials employing ELISpot as an endpointMolecular Thassay, these data suggest that participants with low CD4 nadir can be
enrolled.
Overall, we observed that the HIV-specific T cell response in durably
suppressed PLWH is uniformly detectable with an average frequency
of >1,000 SFUs/106 PBMCs and is maintained over years. Although
the overall frequency of the measured HIV-specific T cell response
in our participant cohort is lower than in untreated HIV infec-
tion,17,25 measured T cell responses were >10 times higher than
memory T cell responses to influenza and yellow fever vaccina-
tion.26,27 In both influenza and yellow fever vaccination, there is no
residual antigen, and the T cell responses measured reflect long-
termmemory. This suggests that the higher frequency of HIV-specific
T cell responses in HIV+ ART+ individuals is maintained by ongoing
low-level antigen presentation from residually infected cells,
consistent with reports of low-level viremia in ART-suppressed
individuals.28,29
A recent study reported a correlation between the T cell response
measured by ELISpot targeting Nef and cell-associated HIV DNA
levels,15 suggesting post-ART detection of HIV Nef expression by
T cells. In our study, no correlation was detected between the magni-
tude of the HIV-specific T cell response (both the summed total HIV
Clade B response and the response to individual HIV proteins) and
the size of the replication-competent reservoir measured by QVOA.
We do not consider these results incompatible. First, as discussed
above, the stability of the HIV-specific T cell response over months
and years observed in our study is consistent with low-level expres-
sion of HIV proteins, including Nef, in ART-suppressed participants.
Second, cell-associated DNA and QVOAmeasure different aspects of
post-ART residual HIV. QVOA measures rare, transcriptionally
quiescent, memory CD4+ T cells that constitute <1% of the totalerapy: Methods & Clinical Development Vol. 15 December 2019 13
Molecular Therapy: Methods & Clinical DevelopmentHIV-infected cells measured by HIV DNA assays.30 Our results
therefore suggest that the HIV-specific T cell response in HIV+
ART+ individuals is not maintained by rare, stochastic reactivation
of CD4+ T cells harboring replication-competent cells, but rather sus-
tained by antigen presentation from more frequent, less quiescent
cells harboring both replication-competent and -incompetent HIV.
In summary, these data suggest that HIV-specific T cell response pre-
ART treatment is largely maintained, albeit at lower frequencies, over
durable ART-mediated HIV suppression. Given consistent rebound
observed following treatment interruption and the lack of observed
correlations between T cell responses and post-treatment control,
therapeutic interventions will be necessary to improve the post-
ART HIV-specific T cell response, particularly to ensure that CD8+
T cells detect and clear replication-competent reservoir virus.
IFN-g ELISpot is themost commonly used immunogenicity endpoint
assay for clinical testing of T cell vaccines and immunotherapies,
including HIV cure. The minimal variation over time of the HIV-
specific T cell response measured by IFN-g ELISpot in HIV+ ART+
individuals has translational implications. We show that group sizes
as small as six participants can provide sufficient power to detect a
GMR of 2 for the HIV-specific T cell responses pre- versus post-vacci-
nation. Data provided by this study will facilitate the design and
powering of future T cell therapies against HIV.
MATERIALS AND METHODS
IRB Approvals
Participants enrolled in one of three cohorts. Participants partici-
pating in the cross-sectional and weekly and monthly longitudinal
studies at UNC enrolled in one of the following IRB-approved studies:
(1) CID 1107, Single Blood Collection Study (IRB #11-15060); (2)
CID 0819, Apheresis Procedures to Obtain Leukocytes for Research
Studies from HIV Positive Participants (08-1575); and (3) The
UNC Women’s Interagency HIV Study (WIHS) (12-1660). Partici-
pants providing the yearly longitudinal samples enrolled in the
SCOPE cohort (IRB 10-01330, NCT00187512).
Review and implementation of all protocols utilized for the collection
of samples for this analysis were approved by the University of North
Carolina at Chapel Hill Biomedical IRB and the UCSF IRB. All par-
ticipants provided written informed consent.
We used HIV-seronegative participants for assay standardization.
These participants were recruited by the UNC Center for AIDS
Research (CFAR) Immunology Core (IRB).
Study Participants and Ethics Statement
Participants were enrolled across three observational cohorts; all pro-
vided written informed consent. For cross-sectional and weekly and
monthly longitudinal studies, participants were enrolled through
either the UNC Chapel Hill HIV Clinical Trials Unit or the WIHS
UNC Chapel Hill site. For yearly longitudinal studies, participants
were enrolled through the SCOPE cohort (NCT00187512) at UCSF.
All experimental protocols were approved by local Institutional14 Molecular Therapy: Methods & Clinical Development Vol. 15 DecemBiomedical Review Boards (ethics numbers: 14-0741, 11-0228, and
13-3613, 12-1660, 10-01330) and performed in accordance with the
relevant guidelines. HIV-seronegative participants for assay stan-
dardization were recruited by the UNC CFAR Immunology Core
(IRB 96-0859).
All participants were receiving stable standard-of-care ART and had
maintained plasma HIV-1 RNA <50 copies/mL and a CD4 T cell
count of >300/mL forR6 months before enrollment. Study character-
istics of the cohorts are summarized in Tables 1 and 2.
PBMC Isolation
Samples (50–100 mL) of apheresis product were collected for this
study. PBMCs were isolated from the product by centrifugation
(1,200 g for 15 min at room temperature) on a Ficoll-Paque density
gradient (GE Healthcare Life Sciences Ficoll-Paque Plus). In brief, the
apheresis product was diluted 1:2.5 in 2% fetal bovine serum (FBS)/
PBS, and 30 mL diluted product was underlaid with 15 mL Ficoll-
Plaque in SepMate tube (SepMate-50 [IVD]) prior to centrifugation.
PBMCs were harvested, then washed three times in 2% FBS/PBS.
Cells were counted and then frozen.31
IFN-g ELISpot
Cryopreserved PBMCs were thawed using Benzonase (25 IU) and res-
ted overnight (18–20 h) at 37C. Overnight rest of cryopreserved
PBMCs helps to removed dead and/or dying cells and generally
results in enhanced measurement of antigen-specific T cell re-
sponses.32–34 The next day, PBMCs were counted using a Muse Cell
Counter (Millipore Sigma) in accordance with the manufacturer’s in-
structions. Samples were counted independently three times; then re-
sults were averaged. The average %CV between counts was <10%. No
minimum cell viability or minimum cell recovery criteria were
applied. Viable cells were suspended at 8  106/mL in R-10 (list)
and 4  105 cells in 50 mL added to ELISpot plates using a calibrated
multi-channel pipette. Notably, 4  105 cells/well is a 2- to 4-fold
higher cell number than typically available for clinical trials, likely af-
fording us higher sensitivity in this study. Plates were placed at 37C,
5% CO2 for 30 min prior to the addition of peptide. Assay peptides
and controls (mock-no peptide, phytohemagglutinin [PHA]
5 mg/mL) had been previously aliquoted into 96-well round-bottom
plates at 2 concentration, sealed to prevent evaporation, and stored
at 80C. Plates were thawed at 37C; then 50 mL of peptide was
added to wells, and the suspension was mixed 7–10 times and then
incubated for 18–20 h at 37C, 5% CO2. Six mock controls were
used, and peptides were tested in quadruplicate. ELISpot plates
were developed as previously described.31 Spots were enumerated
on an AID Reader (ELR081512367) using a standard counting
setting. A reactive T cell response to a peptide pool was defined as
the average of replicate wells >30 SFUs/106 PBMCs and four times
the average of mock wells.31 Zero values were not accepted in any
replicate of antigen-stimulated wells. The average of mock wells
was required to be <25 SFUs/well equating to background <62.5
SFUs/106 cells. No data in the cross-sectional or longitudinal weekly
or monthly studies using prospectively collected samples wereber 2019
www.moleculartherapy.orgexcluded because of high background; several time points in the
longitudinal yearly study that used retrospective samples were
excluded for high background.
Peptides
Two sets of HIV peptides were generated (Sigma-Genosys, USA):
18-mer peptides overlapping by 10 amino acids were synthesized
(Sigma-Genosys, USA) to match the HIV Clade B consensus
sequence (386 peptides) and previously defined HIV CD8+ optimal
peptides (9- to 11-mer peptides).20 Optimal CD8+ peptides were
grouped by protein, 109 Gag/Nef (CTL-A) peptides or 103 non-
Gag/Nef (CTL-B) peptides.
QVOA
QVOA assays were performed as previously described35 to provide a
minimum estimate of replication-competent HIV in 19 partici-
pants.36 Infectious units per million (IUPM) estimates and CIs
were calculated using the SLDAssay R software package.37
Statistical Analysis
The primary outcomes were mock-adjusted (i.e., mock-subtracted)
HIV peptide pools (protein, CTLA, and CTLB) defined as: mean
(HIV pools)  mean (mock). All data are reported as SFUs per 106
PBMCs. Total HIV T cell response was defined as the sum of each
mock-adjusted HIV protein pool: (mean CTLA  mean mock) +
(mean CTLB  mean mock). At least three replicates were used per
HIV peptide pool in all individuals. Visits with high background
(mean mockR25 per 4 105 PBMCs) were excluded from analyses.
Cross-Sectional Data
Spearman rank two-sided tests for correlations were performed.
Cross-sectional data analyses were conducted using GraphPad
Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA,
USA).
Longitudinal Data
To describe within-individual variability over time, %CV was esti-
mated. %CV is a measure of relative variability. A corresponding dis-
tribution-free 95% CI for the pseudo-median CV was calculated. To
inspect factors that may contribute to measurement variation, while
standardizing for within-individual variability, an individual-specific
Z score was calculated for mock-adjusted CTL-A+B and plotted
against covariates of interest. Covariates included number of mea-
sures over time, CV between percent live counts, total cell count,
viable cell count, percent cell recovery following thaw, mock mean,
days between visit and thaw, and days since first measurement.
Additionally, to inspect factors that may be associated with high
or low CTL-A+B values, raw CTL-A+B measurements were
plotted against the same covariates of interest (data not shown). A
marginal non-parametric Kendall’s Tau correlation for clustered
(repeated-measures) data was estimated with a corresponding 95%
Wald CI for CTL-A+B Z scores and covariates of interest, and
raw CTL-A+B scores and covariates of interest.21 Analyses were
conducted separately for (1) weekly, (2) monthly, and (3) yearlyMolecular Thdata (unless noted otherwise). A two-sided 0.05 significance level
was used throughout without adjustment for multiplicity. Statistical
analyses were conducted in SAS version 9.4 (SAS/STAT 14.2) and
R version 3.4.1.Power Analysis: Methods
Statistical power was estimated for future studies that would compare
average within-individual change in mock-adjusted CTLA+B from
baseline to post-vaccine with n = 6, 8, and 12 participants. A GMR
of at least 2 (corresponding to a 2-fold change pre- and post-vaccine)
was anticipated to be scientifically meaningful and was used as the
specific alternative hypothesis. Power for a paired ratio t test and a
nonparametric exact Wilcoxon signed-rank test was calculated.
The assumed between-individual SD for natural log-transformed
CTLA+B was estimated from longitudinal data as the average of
two baseline measurements per individual using weekly and monthly
measurements combined. Correlation within an individual was esti-
mated between paired natural log-transformed CTLA+B measures
at the first time point and at 9 (±3) weeks using Pearson’s correlation.
Empirical power for the exact Wilcoxon signed-rank test was
calculated using 100,000 simulated datasets assuming that natural
log-transformed CTLA+B follows a normal distribution, and the
effect size under the alternative hypothesis was ln(2), i.e., a GMR of
2 on the raw CTLA+B (per 400,000 SFUs) scale. Approximate power
for a paired t test was calculated using the Power procedure paired
means statement in SAS software.SUPPLEMENTAL INFORMATION
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